Xtant Medical commenced the commercial launch of its next-generation synthetic bone graft in the nanOss line, Strata.
nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite. Increased solubility can enhance the bioactivity of the graft, allowing for better integration and remodeling with the surrounding bone tissue during the healing process.
The nanocrystalline structure of HCA used in the nanOss Strata is designed to closely mimic human bone and increase the surface area for improved osteoconductivity and stimulation of the patient’s cellular activity on the surface of the graft after implantation.
Strata is available in compression-resistant preformed strips and prehydrated moldable grafts. Both options are sterile, highly moldable, and quickly absorb blood and other biologic fluids.
Sean Browne, President and CEO of Xtant Medical, stated, “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients.”
Xtant Medical commenced the commercial launch of its next-generation synthetic bone graft in the nanOss line, Strata.
nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite. Increased solubility can enhance the bioactivity of the graft, allowing for better integration...
Xtant Medical commenced the commercial launch of its next-generation synthetic bone graft in the nanOss line, Strata.
nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite. Increased solubility can enhance the bioactivity of the graft, allowing for better integration and remodeling with the surrounding bone tissue during the healing process.
The nanocrystalline structure of HCA used in the nanOss Strata is designed to closely mimic human bone and increase the surface area for improved osteoconductivity and stimulation of the patient’s cellular activity on the surface of the graft after implantation.
Strata is available in compression-resistant preformed strips and prehydrated moldable grafts. Both options are sterile, highly moldable, and quickly absorb blood and other biologic fluids.
Sean Browne, President and CEO of Xtant Medical, stated, “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients.”
Copy to clipboard 
